These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning. Barry PJ; Ronan N; Plant BJ Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594 [TBL] [Abstract][Full Text] [Related]
35. Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. Bresnick K; Arteaga-Solis E; Millar SJ; Laird G; LeCamus C BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34857524 [TBL] [Abstract][Full Text] [Related]
36. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. McGarry ME; McColley SA Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563 [TBL] [Abstract][Full Text] [Related]
37. Cystic fibrosis - Ten promising therapeutic approaches in the current era of care. Somayaji R; Nichols DP; Bell SC Expert Opin Investig Drugs; 2020 Oct; 29(10):1107-1124. PubMed ID: 32744089 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators. Fajac I; Sermet I Cells; 2021 Oct; 10(10):. PubMed ID: 34685773 [TBL] [Abstract][Full Text] [Related]
40. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease. Strub MD; McCray PB Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]